This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forrest, A
Right arrow Articles by Schentag, J J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forrest, A
Right arrow Articles by Schentag, J J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 May; 37(5): 1073-1081

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

A Forrest, D E Nix, C H Ballow, T F Goss, M C Birmingham and J J Schentag

Center for Clinical Pharmacy Research, School of Pharmacy, State University of New York, Buffalo 14260.

ABSTRACT

Seventy-four acutely ill patients were treated with intravenous ciprofloxacin at dosages ranging between 200 mg every 12 h and 400 mg every 8 h. A population pharmacokinetic-pharmacodynamic analysis relating drug exposure (and other factors) to infectious outcome was performed. Plasma samples were obtained and assayed for ciprofloxacin by high-performance liquid chromatography. Samples from patients were frequently cultured so that the day of bacterial eradication could be determined. The pharmacokinetic data were fitted by iterative two-stage analysis, assuming a linear two-compartment model. Logistic regression was used to model ciprofloxacin exposure (and other potential covariates) versus the probabilities of achieving clinical and microbiologic cures. The same variables were also modelled versus the time to bacterial eradication by proportional hazards regression. The independent variables considered were dose, site of infection, infecting organism and the MIC for it, percent time above the MIC, peak, peak/MIC ratio, trough, trough/MIC ratio, 24-h area under the concentration-time curve (AUC), AUC/MIC ratio (AUIC), presence of other active antibacterial agents, and patient characteristics. The most important predictor for all three measures of ciprofloxacin pharmacodynamics was the AUIC. A 24-h AUIC of 125 SIT-1.h (inverse serum inhibitory titer integrated over time) was found to be a significant breakpoint for probabilities of both clinical and microbiologic cures. At an AUIC below 125 (19 patients), the percent probabilities of clinical and microbiologic cures were 42 and 26%, respectively. At an AUIC above 125 (45 patients), the probabilities were 80% (P < 0.005) and 82% (P < 0.001), respectively. There were two significant breakpoints in the time-to-bacterial-eradication data. At an AUIC below 125 (21 patients), the median time to eradication exceeded 32 days; at an AUIC of 125 to 250 (15 patients), time to eradication was 6.6 days: and at AUIC above 250 (28 patients), the median time to eradication was 1.9 days (groups differed; P < 0.005). These findings, when combined with pharmacokinetic data reported in the companion article, provide the rationale and tools needed for targeting the dosage of intravenous ciprofloxacin to individual patients' pharmacokinetics and their bacterial pathogens' susceptibilities. An a priori dosing algorithm (based on MIC, patient creatine clearance and weight, and the clinician-specified AUIC target) was developed. This approach was shown, retrospectively, to be more precise than current guidelines, and it can be used to achieve more rapid bacteriologic and clinical responses to ciprofloxacin, as a consequence of targeting the AUIC.

Antimicrob Agents Chemother. 1993 May; 37(5): 1073-1081




This article has been cited by other articles:

  • Allou, N., Cambau, E., Massias, L., Chau, F., Fantin, B. (2009). Impact of Low-Level Resistance to Fluoroquinolones Due to qnrA1 and qnrS1 Genes or a gyrA Mutation on Ciprofloxacin Bactericidal Activity in a Murine Model of Escherichia coli Urinary Tract Infection. Antimicrob. Agents Chemother. 53: 4292-4297 [Abstract] [Full Text]  
  • Singh, R., Ledesma, K. R., Chang, K.-T., Hou, J.-G., Prince, R. A., Tam, V. H. (2009). Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother 64: 556-562 [Abstract] [Full Text]  
  • Kimko, H., Xu, X., Nandy, P., Samtani, M. N., Strauss, R. S., Bagchi, P., Noel, G. J. (2009). Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 3371-3374 [Abstract] [Full Text]  
  • Udekwu, K. I., Parrish, N., Ankomah, P., Baquero, F., Levin, B. R. (2009). Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63: 745-757 [Abstract] [Full Text]  
  • Launay, E., Joram, N., Jacqueline, C., Miegeville, A. F., Caillon, J., Potel, G., Roze, J. C., Gras-Le Guen, C. (2009). Efficacy of Ciprofloxacin in an Experimental Model of Escherichia coli Chorioamnionitis in Rabbits. Antimicrob. Agents Chemother. 53: 1624-1627 [Abstract] [Full Text]  
  • DeFife, R., Scheetz, M. H., Feinglass, J. M., Postelnick, M. J., Scarsi, K. K. (2009). Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin. Antimicrob. Agents Chemother. 53: 1074-1079 [Abstract] [Full Text]  
  • Crandon, J. L, Kuti, J. L, Jones, R. N, Nicolau, D. P (2009). Comparison of 2002-2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance. The Annals of Pharmacotherapy 43: 220-227 [Abstract] [Full Text]  
  • MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
  • Masterton, R. G., Galloway, A., French, G., Street, M., Armstrong, J., Brown, E., Cleverley, J., Dilworth, P., Fry, C., Gascoigne, A. D., Knox, A., Nathwani, D., Spencer, R., Wilcox, M. (2008). Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62: 5-34 [Abstract] [Full Text]  
  • Schmidt, S., Banks, R., Kumar, V., Rand, K. H., Derendorf, H. (2008). Clinical Microdialysis in Skin and Soft Tissues: An Update. J Clin Pharmacol 48: 351-364 [Abstract] [Full Text]  
  • Kiem, S., Schentag, J. J. (2008). Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid. Antimicrob. Agents Chemother. 52: 24-36 [Full Text]  
  • Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Stromback, A., Hughes, D., Cars, O. (2007). Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother 60: 795-801 [Abstract] [Full Text]  
  • Turnidge, J., Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. Clin. Microbiol. Rev. 20: 391-408 [Abstract] [Full Text]  
  • Meagher, A. K., Passarell, J. A., Cirincione, B. B., Van Wart, S. A., Liolios, K., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2007). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections. Antimicrob. Agents Chemother. 51: 1939-1945 [Abstract] [Full Text]  
  • Lee, C. K. K., Boyle, M. P., Diener-West, M., Brass-Ernst, L., Noschese, M., Zeitlin, P. L. (2007). Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis. Chest 131: 796-802 [Abstract] [Full Text]  
  • Parry, C. M., Ho, V. A., Phuong, L. T., Bay, P. V. B., Lanh, M. N., Tung, L. T., Tham, N. T. H., Wain, J., Hien, T. T., Farrar, J. J. (2007). Randomized Controlled Comparison of Ofloxacin, Azithromycin, and an Ofloxacin-Azithromycin Combination for Treatment of Multidrug-Resistant and Nalidixic Acid-Resistant Typhoid Fever. Antimicrob. Agents Chemother. 51: 819-825 [Abstract] [Full Text]  
  • Murillo, O., Domenech, A., Garcia, A., Tubau, F., Cabellos, C., Gudiol, F., Ariza, J. (2006). Efficacy of High Doses of Levofloxacin in Experimental Foreign-Body Infection by Methicillin-Susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 4011-4017 [Abstract] [Full Text]  
  • Randall, L. P., Cooles, S. W., Coldham, N. C., Stapleton, K. S., Piddock, L. J. V., Woodward, M. J. (2006). Modification of Enrofloxacin Treatment Regimens for Poultry Experimentally Infected with Salmonella enterica Serovar Typhimurium DT104 To Minimize Selection of Resistance. Antimicrob. Agents Chemother. 50: 4030-4037 [Abstract] [Full Text]  
  • Odenholt, I., Cars, O. (2006). Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 58: 960-965 [Abstract] [Full Text]  
  • Burkhardt, O., Lehmann, C., Madabushi, R., Kumar, V., Derendorf, H., Welte, T. (2006). Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. J Antimicrob Chemother 58: 822-829 [Abstract] [Full Text]  
  • Zhang, X., Overholser, B. R., Kays, M. B., Sowinski, K. M. (2006). Gatifloxacin pharmacokinetics in healthy men and women.. J Clin Pharmacol 46: 1154-1162 [Abstract] [Full Text]  
  • Bakker-Woudenberg, I. A. J. M., ten Kate, M. T., Goessens, W. H. F., Mouton, J. W. (2006). Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection.. Antimicrob. Agents Chemother. 50: 2919-2925 [Abstract] [Full Text]  
  • LeBlanc, J. M., Dasta, J. F., Pruchnicki, M. C., Schentag, J. J. (2006). Impact of disease States on the pharmacokinetics and pharmacodynamics of Angiotensin-converting enzyme inhibitors.. J Clin Pharmacol 46: 968-980 [Abstract] [Full Text]  
  • Pea, F., Poz, D., Viale, P., Pavan, F., Furlanut, M. (2006). Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 58: 380-386 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Kiser, T. H., Hoody, D. W., Obritsch, M. D., Wegzyn, C. O., Bauling, P. C., Fish, D. N. (2006). Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.. Antimicrob. Agents Chemother. 50: 1937-1945 [Abstract] [Full Text]  
  • Griffith, D. C., Corcoran, E., Lofland, D., Lee, A., Cho, D., Lomovskaya, O., Dudley, M. N. (2006). Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy?. Antimicrob. Agents Chemother. 50: 1628-1632 [Abstract] [Full Text]  
  • Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., Andes, D. (2006). Voriconazole therapeutic drug monitoring.. Antimicrob. Agents Chemother. 50: 1570-1572 [Abstract] [Full Text]  
  • Bhavnani, S. M., Passarell, J. A., Owen, J. S., Loutit, J. S., Porter, S. B., Ambrose, P. G. (2006). Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 50: 994-1000 [Abstract] [Full Text]  
  • Fukuda, Y., Yanagihara, K., Ohno, H., Higashiyama, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Mizuta, Y., Tashiro, T., Kohno, S. (2006). In Vivo Efficacies and Pharmacokinetics of DX-619, a Novel Des-Fluoro(6) Quinolone, against Streptococcus pneumoniae in a Mouse Lung Infection Model. Antimicrob. Agents Chemother. 50: 121-125 [Abstract] [Full Text]  
  • Deziel, M. R., Heine, H., Louie, A., Kao, M., Byrne, W. R., Basset, J., Miller, L., Bush, K., Kelly, M., Drusano, G. L. (2005). Effective Antimicrobial Regimens for Use in Humans for Therapy of Bacillus anthracis Infections and Postexposure Prophylaxis. Antimicrob. Agents Chemother. 49: 5099-5106 [Abstract] [Full Text]  
  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Washington, C. B., Hou, S. Y. E., Campanella, C., Hughes, N., Brown, S., Berner, B. (2005). Pharmacokinetics and Pharmacodynamics of a Novel Extended-Release Ciprofloxacin in Healthy Volunteers. J Clin Pharmacol 45: 1236-1244 [Abstract] [Full Text]  
  • Zelenitsky, S., Ariano, R., Harding, G., Forrest, A. (2005). Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations. Antimicrob. Agents Chemother. 49: 4009-4014 [Abstract] [Full Text]  
  • Cazzola, M., Matera, M. G., Donnarumma, G., Tufano, M. A., Sanduzzi, A., Marchetti, F., Blasi, F. (2005). Pharmacodynamics of Levofloxacin in Patients With Acute Exacerbation of Chronic Bronchitis. Chest 128: 2093-2098 [Abstract] [Full Text]  
  • Firsov, A. A., Lubenko, I. Y., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2005). Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones. Antimicrob. Agents Chemother. 49: 2642-2647 [Abstract] [Full Text]  
  • Martinez, F. J., Grossman, R. F., Zadeikis, N., Fisher, A. C., Walker, K., Ambruzs, M. E., Tennenberg, A. M. (2005). Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 25: 1001-1010 [Abstract] [Full Text]  
  • Booker, B. M., Smith, P. F., Forrest, A., Bullock, J., Kelchlin, P., Bhavnani, S. M., Jones, R. N., Ambrose, P. G. (2005). Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi. Antimicrob. Agents Chemother. 49: 1775-1781 [Abstract] [Full Text]  
  • Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., Drusano, G. L. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55: 601-607 [Abstract] [Full Text]  
  • Cook, A. M. (2005). Pharmacokinetic Alterations of Antimicrobials in the Critically Ill. Journal of Pharmacy Practice 18: 75-83 [Abstract]  
  • Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., Plesiat, P. (2005). Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother 55: 518-522 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Moine, P., Cherbuliez, C., Peytavin, G., Fantin, B., Kohler, T. (2005). Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 49: 1046-1054 [Abstract] [Full Text]  
  • Capparelli, E. V., Reed, M. D., Bradley, J. S., Kearns, G. L., Jacobs, R. F., Damle, B. D., Blumer, J. L., Grasela, D. M. (2005). Pharmacokinetics of Gatifloxacin in Infants and Children. Antimicrob. Agents Chemother. 49: 1106-1112 [Abstract] [Full Text]  
  • Masterton, R. G., Kuti, J. L., Turner, P. J., Nicolau, D. P. (2005). The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 55: 71-77 [Abstract] [Full Text]  
  • Ariano, R. E, Nyhlen, A., Donnelly, J P., Sitar, D. S, Harding, G. K., Zelenitsky, S. A (2005). Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia. The Annals of Pharmacotherapy 39: 32-38 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Van Wart, S., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., Echols, R., Grasela, D. M. (2004). Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 48: 4766-4777 [Abstract] [Full Text]  
  • Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
  • Preston, S. L (2004). The Importance of Appropriate Antimicrobial Dosing: Pharmacokinetic and Pharmacodynamic Considerations. The Annals of Pharmacotherapy 38: S14-S18 [Abstract] [Full Text]  
  • Kuti, J. L., Nightingale, C. H., Nicolau, D. P. (2004). Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrob. Agents Chemother. 48: 2464-2470 [Abstract] [Full Text]  
  • Meagher, A. K., Forrest, A., Dalhoff, A., Stass, H., Schentag, J. J. (2004). Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin. Antimicrob. Agents Chemother. 48: 2061-2068 [Abstract] [Full Text]  
  • Strijack, C., Harding, G. K. M., Ariano, R. E., Zelenitsky, S. A. (2004). Peritoneal Fluid Titer Test for Peritoneal Dialysis-Related Peritonitis. Antimicrob. Agents Chemother. 48: 1719-1726 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Peytavin, G., Isturiz, R., Moine, P., Rieux, V., Cherbuliez, C., Pechere, J. C., Fantin, B., Kohler, T. (2004). Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 48: 765-773 [Abstract] [Full Text]  
  • Phillips, I., Casewell, M., Cox, T., De Groot, B., Friis, C., Jones, R., Nightingale, C., Preston, R., Waddell, J. (2004). Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J Antimicrob Chemother 53: 28-52 [Abstract] [Full Text]  
  • Otsu, Y., Yanagihara, K., Fukuda, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J.-i., Tashiro, T., Murata, I., Kohno, S. (2003). In Vivo Efficacy of a New Quinolone, DQ-113, against Streptococcus pneumoniae in a Mouse Model. Antimicrob. Agents Chemother. 47: 3699-3703 [Abstract] [Full Text]  
  • Andes, D., Craig, W. A. (2003). Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model. Antimicrob. Agents Chemother. 47: 3935-3941 [Abstract] [Full Text]  
  • Barger, A., Fuhst, C., Wiedemann, B. (2003). Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 52: 893-898 [Abstract] [Full Text]  
  • Joukhadar, C., Stass, H., Muller-Zellenberg, U., Lackner, E., Kovar, F., Minar, E., Muller, M. (2003). Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans. Antimicrob. Agents Chemother. 47: 3099-3103 [Abstract] [Full Text]  
  • Pea, F., Pavan, F., Nascimben, E., Benetton, C., Scotton, P. G., Vaglia, A., Furlanut, M. (2003). Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy. Antimicrob. Agents Chemother. 47: 3104-3108 [Abstract] [Full Text]  
  • Zelenitsky, S. A., Harding, G. K. M., Sun, S., Ubhi, K., Ariano, R. E. (2003). Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52: 668-674 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials. The Annals of Pharmacotherapy 37: 1478-1488 [Abstract] [Full Text]  
  • Amsden, G. W, Owens, R. C Jr, Bertino, J. S Jr (2003). AUIC in Humans: A Fact-Based Discussion. The Annals of Pharmacotherapy 37: 1518-1521 [Full Text]  
  • Scaglione, F., Mouton, J. W., Mattina, R., Fraschini, F. (2003). Pharmacodynamics of Levofloxacin and Ciprofloxacin in a Murine Pneumonia Model: Peak Concentration/MIC versus Area under the Curve/MIC Ratios. Antimicrob. Agents Chemother. 47: 2749-2755 [Abstract] [Full Text]  
  • Paladino, J. A., Sunderlin, J. L., Forrest, A., Schentag, J. J. (2003). Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52: 457-463 [Abstract] [Full Text]  
  • Ambrose, P. G., Bhavnani, S. M., Cirincione, B. B., Piedmonte, M., Grasela, T. H. (2003). Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 52: 435-440 [Abstract] [Full Text]  
  • Amsden, G. W., Whitaker, A.-M., Johnson, P. W. (2003). Lack of Bioequivalence of Levofloxacin When Coadministered with a Mineral-Fortified Breakfast of Juice and Cereal. J Clin Pharmacol 43: 990-995 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
  • Greko, C., Finn, M., Franklin, A., Bengtsson, B. (2003). Pharmacokinetic/pharmacodynamic relationship of danofloxacin against Mannheimia haemolytica in a tissue-cage model in calves. J Antimicrob Chemother 52: 253-257 [Abstract] [Full Text]  
  • Fagon, J-Y., Chastre, J. (2003). Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients. Eur Respir J 22: 77s-83s [Abstract] [Full Text]  
  • Nicolau, D. P., Mattoes, H. M., Banevicius, M., Xuan, D., Nightingale, C. H. (2003). Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcuspneumoniae in the Thigh Infection Model. Antimicrob. Agents Chemother. 47: 1630-1635 [Abstract] [Full Text]  
  • Zelenitsky, S. A., Ariano, R. E., Iacovides, H., Sun, S., Harding, G. K. M. (2003). AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 51: 905-911 [Abstract] [Full Text]  
  • Aliabadi, F. S., Landoni, M. F., Lees, P. (2003). Pharmacokinetics (PK), Pharmacodynamics (PD), and PK-PD Integration of Danofloxacin in Sheep Biological Fluids. Antimicrob. Agents Chemother. 47: 626-635 [Abstract] [Full Text]  
  • Ellbogen, M. H., Olsen, K. M., Gentry-Nielsen, M. J., Preheim, L. C. (2003). Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 51: 83-91 [Abstract] [Full Text]  
  • Wallace, A. W., Victory, J. M., Amsden, G. W. (2003). Lack of Bioequivalence of Gatifloxacin When Coadministered with Calcium-Fortified Orange Juice in Healthy Volunteers. J Clin Pharmacol 43: 92-96 [Abstract] [Full Text]  
  • Meyerhoff, A., Murphy, D., Tice, A. D., Inglesby, T., O'Toole, T. (2002). Guidelines for Treatment of Anthrax. JAMA 288: 1848-1849 [Full Text]  
  • Xuan, D., Banevicius, M., Capitano, B., Kim, M.-K., Nightingale, C., Nicolau, D. (2002). Pharmacodynamic Assessment of Ertapenem (MK-0826) against Streptococcuspneumoniae in a Murine Neutropenic Thigh Infection Model. Antimicrob. Agents Chemother. 46: 2990-2995 [Abstract] [Full Text]  
  • Sarasola, P., Lees, P., AliAbadi, F. S., McKellar, Q. A., Donachie, W., Marr, K. A., Sunderland, S. J., Rowan, T. G. (2002). Pharmacokinetic and Pharmacodynamic Profiles of Danofloxacin Administered by Two Dosing Regimens in Calves Infected with Mannheimia (Pasteurella) haemolytica. Antimicrob. Agents Chemother. 46: 3013-3019 [Abstract] [Full Text]  
  • Zelenitsky, S. A., Ariano, R. E., Harding, G. K. M., Silverman, R. E. (2002). Antibiotic Pharmacodynamics in Surgical Prophylaxis: an Association between Intraoperative Antibiotic Concentrations and Efficacy. Antimicrob. Agents Chemother. 46: 3026-3030 [Abstract] [Full Text]  
  • Bakker-Woudenberg, I. A. J. M., ten Kate, M. T., Guo, L., Working, P., Mouton, J. W. (2002). Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection. Antimicrob. Agents Chemother. 46: 2575-2581 [Abstract] [Full Text]  
  • Sanchez Navarro, M. D., Sayalero Marinero, M. L., Sanchez Navarro, A. (2002). Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. J Antimicrob Chemother 50: 67-72 [Abstract] [Full Text]  
  • Andes, D., Craig, W. A. (2002). Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models. Antimicrob. Agents Chemother. 46: 1665-1670 [Abstract] [Full Text]  
  • Odenholt, I., Lowdin, E., Gustafsson, I., Cars, O. (2002). Pharmacodynamics of Moxifloxacin against Streptococcus pyogenes in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 46: 2046-2048 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P. (2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 1503-1509 [Abstract] [Full Text]  
  • Chastre, J., Fagon, J.-Y. (2002). Ventilator-associated Pneumonia. Am. J. Respir. Crit. Care Med. 165: 867-903 [Abstract] [Full Text]  
  • Ambrose, P. G., Owens, R. C. Jr, Garvey, M. J., Jones, R. N. (2002). Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 49: 445-453 [Abstract] [Full Text]  
  • Lister, P. D. (2002). Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on Eradication. Antimicrob. Agents Chemother. 46: 69-74 [Abstract] [Full Text]  
  • Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D. E., Rubinstein, E., Wise, R., Consensus Group on Resistance and Prescribing in R, T. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49: 31-40 [Abstract] [Full Text]  
  • Peterson, M. L., Hovde, L. B., Wright, D. H., Brown, G. H., Hoang, A. D., Rotschafer, J. C. (2002). Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 46: 203-210 [Abstract] [Full Text]  
  • Montgomery, M. J., Beringer, P. M., Aminimanizani, A., Louie, S. G., Shapiro, B. J., Jelliffe, R., Gill, M. A. (2001). Population Pharmacokinetics and Use of Monte Carlo Simulation To Evaluate Currently Recommended Dosing Regimens of Ciprofloxacin in Adult Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 45: 3468-3473 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., McCoig, C. C., Michelow, I. C., Ghaffar, F., Jafri, H. S., Hardy, R. D., Patel, C., Olsen, K., McCracken, G. H. Jr. (2001). Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. Antimicrob. Agents Chemother. 45: 3092-3097 [Abstract] [Full Text]  
  • Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., Pierce, P. F. (2001). Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 45: 2793-2797 [Abstract] [Full Text]  
  • MacGowan, A. P., Rogers, C. A., Holt, H. A., Wootton, M., Bowker, K. E. (2001). Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection. Antimicrob. Agents Chemother. 45: 2916-2921 [Abstract] [Full Text]  
  • Malone, R. S., Fish, D. N., Abraham, E., Teitelbaum, I. (2001). Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 45: 2949-2954 [Abstract] [Full Text]  
  • Rello, J., Paiva, J. A., Baraibar, J., Barcenilla, F., Bodi, M., Castander, D., Correa, H., Diaz, E., Garnacho, J., Llorio, M., Rios, M., Rodriguez, A., Sole-Violan, J. (2001). International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-Associated Pneumonia. Chest 120: 955-970 [Abstract] [Full Text]  
  • Zhanel, G. G., Saunders, D. G., Hoban, D. J., Karlowsky, J. A. (2001). Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans. Antimicrob. Agents Chemother. 45: 2018-2022 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»